PD-L1 expression

ssRAB integrated with mobile CBCT-guided cryobiopsy had a high diagnostic yield for GGO-predominant PPNs with a favorable safety profile.

Moreover, low RAD18 expression predicted a favorable response to immune checkpoint blockade therapy, while its high expression correlated with anti-PD-1 resistance in triple-negative breast cancer. Collectively, our findings identify RAD18 as a potential pan-cancer prognostic biomarker and immunotherapeutic target, with targeting RAD18 holding promise for reversing immunotherapy resistance in solid tumors.

Collectively, these findings suggest that ASF1B deficiency exerts anti-tumor effects and anti-tumor immunity by regulating p53-related ferroptosis.

Both KRAS "OFF"" G12C inhibitors, sotorasib and adagrasib, are considered standard second-line therapy, albeit with a modest progression-free survival benefit over standard chemotherapy. Critical clinical questions remain open regarding the optimal patient population for combinations, the influence of co-occurring genomic alterations, intracranial activity of KRAS inhibitors and dose optimization. This review synthesizes current evidence on the biology, clinical efficacy, safety, and practical considerations for treating KRAS G12C-mutant NSCLC, providing clinicians with an up-to-date, evidence-based framework for therapeutic decision-making and highlighting areas requiring further investigation.

The immune microenvironment was found to influence the response to immunotherapy in EBVaGC. Detailed characterization of the immune microenvironment may enhance the selection of patients with EBVaGCs likely to respond to immunotherapy.

Despite these insights, its roles in myeloid-derived suppressor cells, neutrophils, and other stromal subsets remain poorly understood. Therefore, investigating PGRN's influence on these cells is crucial for understanding tumor progression and therapeutic resistance and may reveal novel strategies to disrupt PGRN-dependent inflammatory circuits and enhance anti-tumor immunity.

Gemcitabine pretreatment upregulated PD-L1 expression and enhanced CAR-T-mediated cytotoxicity. These findings demonstrate the feasibility of second-generation PD-L1 CAR-T cells, demonstrating preclinical efficacy and specificity, and validating a therapeutic strategy that targets the tumor microenvironment for these challenging cancers.

This case illustrates herpes zoster reactivation during Pembrolizumab-based chemo-immunotherapy in metastatic NSCLC. It emphasizes the importance of systematically excluding infectious causes in new cutaneous eruptions under immunotherapy and supports multidisciplinary management. These findings also highlight the need to further explore VZV screening and vaccination strategies in cancer patients undergoing immunosuppressive treatments.

Our findings reveal pervasive m6A dysregulation with superior predictive performance compared to conventional approaches. The links between RNA methylation and tumor immunity establish m6A signatures as actionable biomarkers for precision oncology.

P2, N=30, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting

Coordinated expression of multiple inhibitory immune checkpoints identifies an inflamed tumor microenvironment associated with improved outcomes following PD-1 blockade in HNSCC.

The up-LC14A1 model represents a patient-derived HBV-HCC system capturing a clonally stable but dynamically regulated HLA-G-mediated immune-tolerant state. This platform enables mechanistic investigation of immune escape and provides a translational model for testing targeted immunotherapies in HBV-associated HCC.